A patient's own immune system is their best weapon against cancer. When cancer finds a way to overcome your immune system, it develops into full blown disease.
Dendritic cells direct immune responses to keep you healthy. These cells are often dysfunctional in cancer patients.
At Guardian Bio, our goal is to take back control of the immune system with an approach focused on creating a personalized cell therapy based on dendritic cells. Our product drives anti-tumor activity through eliciting a diverse yet targeted immune response - mobilizing the entire army for the fight.
We take stem cells from patients and turn them into cancer-targeted dendritic cells. Injecting our product back into patients will revitalize their immune system and give it the help it needs to win.
Our dendritic cell-based platform has the potential to partner with numerous cutting edge technologies to bring better therapies to patients, including neoantigen vaccines, oncolytic viruses, checkpoint inhibitors, and other cell therapies. We will also be expanding our platform to chronic infectious diseases and autoimmunity. Contact us if you would like to discuss further.